Inspira™ Technologies Flagship Technology to be Showcased at Arab Health Expo 2025 in Dubai

Rhea-AI Summary

Inspira Technologies (NASDAQ: IINN) has announced its participation in the Arab Health 2025 exhibition, where it will showcase its FDA-cleared INSPIRA™ ART100 cardiopulmonary bypass system. The event, scheduled for January 27-30, 2025, at the Dubai World Trade Center, is expected to attract over 3,800 exhibitors from more than 180 countries.

The INSPIRA ART100 system is designed to oxygenate blood and remove carbon dioxide, effectively taking over heart and lung functions in critical care patients. The system features proprietary software for setup guidance, advanced customization options, and built-in alarm management with troubleshooting solutions. It offers up to four hours of emergency uptime, maintains a small footprint, and is compatible with various market-available disposables.

Positive

• FDA clearance obtained for INSPIRA ART100 system
• System compatibility with various market disposables
• Advanced features including proprietary software and alarm management
• Four-hour emergency uptime capability

Negative

• None.

Insights

Medical Research Analyst

The Arab Health Expo showcase of the FDA-cleared INSPIRA™ ART100 represents a standard marketing event without immediate financial impact. While the system's cardiopulmonary bypass capabilities and proprietary software features are noteworthy, trade show presentations rarely translate to significant near-term revenue or stock movements.

The 180-country attendance and 3,800 exhibitors provide visibility but do not guarantee commercial success. For a micro-cap company with a $23.1 million market capitalization, the focus should be on actual sales execution and market penetration rather than exhibition appearances.

The FDA clearance mentioned is a historical achievement rather than new information. Without specific partnership announcements, distribution agreements, or sales targets from this event, the news lacks material substance for investors.

Visitors at Glo-Med Network Inc's booth can explore Inspira's cutting-edge respiratory solutions, with the FDA-cleared INSPIRA™ ART100, showcasing the future of respiratory care

RA'ANANA, Israel, Jan. 7, 2025 /PRNewswire/ -- Inspira Technologies Oxy B.H.N. Ltd. (NASDAQ: IINN) (NASDAQ: IINNW), ("Inspira Technologies," "Inspira" or the "Company"), a groundbreaking respiratory support technology company, is pleased to announce that the INSPIRA™ ART100, a cardiopulmonary bypass system will be showcased at Arab Health 2025, one of the largest healthcare exhibitions in the Middle East, expected to have over 3,800 exhibitors and over 180 visiting countries.

 

The event will take place from January 27^th to January 30^th, 2025 at the Dubai World Trade Center, in Dubai, United Arab Emirates.

The INSPIRA ART100 system has already attained U.S. Food and Drug Administration ("FDA") clearance for Cardiopulmonary Bypass procedures. The INSPIRA ART100 system utilizes a technique that adds oxygen to the blood and removes carbon dioxide, with the enriched blood being circulated back to the patient, taking over the functionality of the heart and/or lungs in critical care patients.

The INSPIRA ART100 is equipped with the Company's signature proprietary software designed to assist medical teams to navigate through the setup process, as well as advanced features that include customizing procedures for improved patient care. It is also equipped with a built-in alarm management that offers immediate troubleshooting solutions to the medical team. The system has a small footprint, provides up to four hours of uptime in emergency scenarios, and can be used with various disposables available on the market.

Dagi Ben-Noon, CEO of Inspira Technologies said:

"The Arab Health Expo 2025 in Dubai serves as a global platform to present our innovative technologies to healthcare leaders and companies from around the world. This is an incredible opportunity to explore new markets and forge partnerships that can drive the global adoption of our cutting-edge respiratory solutions."

About the Arab Health Conference

Arab Health 2025 is the leading healthcare exhibition and congress in the Middle East, bringing together global healthcare professionals, manufacturers, and innovators to showcase cutting-edge medical technologies, products, and services.

Inspira™ Technologies OXY B.H.N. Ltd.

Inspira Technologies is an innovative medical technology company in the life support and respiratory treatment arena. The Company has developed a breakthrough Augmented Respiration Technology (INSPIRA™ ART), a groundbreaking device poised to revolutionize the $19 billion mechanical ventilation market. With 20 million intensive care unit patients with acute respiratory failure each year, many of whom rely on mechanical ventilators, the INSPIRA ART offers a potential alternative by elevating and stabilizing decreasing oxygen saturation levels in minutes without a ventilator, with patients being awake during treatment. The INSPIRA ART is being equipped with a clip-on HYLA™ blood sensor, a real-time continuous blood monitoring technology, aiming to alert physicians of changes in a patient's condition without the need for intermittent actual blood samples, aiming to support physicians in making informed decisions.

In June and July 2024, respectively, the Company's INSPIRA^™ ART100 system has obtained FDA 510(k) clearance for use in CBP procedures, along with the Israeli AMAR certification for both Extra-Corporeal Membrane Oxygenation and Cardiopulmonary Bypass procedures.

The Company's other products and technologies, including the INSPIRA ART also known as the INSPIRA™ ART500 or Gen 2, the INSPIRA™ Cardi-ART portable modular device, VORTX™ Oxygen Delivery System, and HYLA™ blood sensor, are currently being designed and developed, and have not yet been tested or used in humans nor approved by any regulatory entity.

For more information, please visit our corporate website at https://inspira-technologies.com

Forward-Looking Statements
This press release contains express or implied forward-looking statements pursuant to U.S. Federal securities laws. These forward-looking statements and their implications are based on the current expectations of the management of the Company only and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. For example, the Company is using forward-looking statements when it discusses the potential benefits of its products and technologies, that Arab Health 2025 is an incredible opportunity to explore new markets and forge partnerships that can drive the global adoption of the Company's cutting-edge respiratory solutions, the size of its target market and that its development of innovative life support technology could disrupt the $19 billion mechanical ventilation market. These forward-looking statements and their implications are based solely on the current expectations of the Company's management and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Except as otherwise required by law, the Company undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. More detailed information about the risks and uncertainties affecting the Company is contained under the heading "Risk Factors" in the Company's annual report on Form 20-F for the fiscal year ended December 31, 2023 filed with the U.S. Securities and Exchange Commission (the "SEC"), which is available on the SEC's website at www.sec.gov.

Contact:
For more information, contact:

Inspira Technologies – Media Relations

Email: info@inspirao2.com

Phone: +972-9-9664485

Copyright © 2018-2025 Inspira Technologies OXY B.H.N. LTD., All rights reserved.

Logo - https://mma.prnewswire.com/media/1668495/Inspira_Technologies_Logo.jpg

View original content:https://www.prnewswire.com/news-releases/inspira-technologies-flagship-technology-to-be-showcased-at-arab-health-expo-2025-in-dubai-302344366.html

SOURCE Inspira Technologies

FAQ

When will Inspira Technologies (IINN) showcase its ART100 system at Arab Health 2025?

Inspira Technologies will showcase the INSPIRA ART100 system at Arab Health 2025 from January 27th to January 30th, 2025, at the Dubai World Trade Center.

What regulatory approvals has IINN's INSPIRA ART100 system received?

The INSPIRA ART100 system has received FDA clearance for Cardiopulmonary Bypass procedures.

What are the key features of IINN's INSPIRA ART100 system?

The INSPIRA ART100 features proprietary setup software, customizable procedures, built-in alarm management with troubleshooting, four-hour emergency uptime, small footprint, and compatibility with various market disposables.

How does IINN's INSPIRA ART100 system function in critical care?

The system adds oxygen to blood and removes carbon dioxide, with the enriched blood being circulated back to the patient, effectively taking over heart and/or lung functionality in critical care patients.